Compare PKST & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKST | CRVS |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.0M | 546.7M |
| IPO Year | N/A | 2016 |
| Metric | PKST | CRVS |
|---|---|---|
| Price | $15.13 | $21.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $17.50 | ★ $28.00 |
| AVG Volume (30 Days) | 187.4K | ★ 7.6M |
| Earning Date | 02-19-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $221,496,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.03 | N/A |
| 52 Week Low | $10.35 | $2.54 |
| 52 Week High | $15.40 | $26.95 |
| Indicator | PKST | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 69.99 | 71.27 |
| Support Level | $13.74 | $20.34 |
| Resistance Level | $14.33 | $26.95 |
| Average True Range (ATR) | 0.38 | 2.16 |
| MACD | 0.12 | 1.07 |
| Stochastic Oscillator | 93.31 | 72.23 |
Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets in majorly high-growth coastal and sunbelt markets. The company has two reportable segments: Industrial and Office. The Industrial segment consists of industrial outdoor storage properties which have a low building-to-land ratio, or low coverage, maximizing yard space for the display, movement, and storage of materials and equipment. The Office segment includes office, R&D and data center properties.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).